Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349959 · ClinicalTrials.gov registry record · Phase 2
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
A Phase 2 study of Recurrent Breast Carcinoma and Triple-Negative Breast Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 7
- Study locations
NCT01349959 is a Phase 2 study of Recurrent Breast Carcinoma and Triple-Negative Breast Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 58 participants, below the 288-participant average among 29 other Recurrent Breast Carcinoma trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT01349959, a Phase 2 study of Recurrent Breast Carcinoma and Triple-Negative Breast Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 7
- Study locations
Study Summary
This phase II trial studies how well giving azacitidine and entinostat work in treating patients with advanced breast cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with entinostat may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Azacitidine
- OTHER Laboratory Biomarker Analysis
- DRUG Entinostat
- OTHER Pharmacological Study
Study Locations (7)
California
- City of Hope Comprehensive Cancer Center - Duarte
- USC / Norris Comprehensive Cancer Center - Los Angeles
- University of California Davis Comprehensive Cancer Center - Sacramento
Minnesota
- Unity Hospital - Fridley
- Metro Minnesota Community Oncology Research Consortium - Saint Louis Park
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2011-08-15 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349959
The ClinicalTrials.gov registry entry for NCT01349959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 29 other Recurrent Breast Carcinoma trials with a reported enrollment target (80% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Azacitidine is the first listed.
NCT01349959 reports 7 study locations spanning 4 distinct geographic areas - top geographies include California, Minnesota, Maryland.
Frequently Asked Questions
What is clinical trial NCT01349959 about?
NCT01349959 is a clinical study titled "Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer". This phase II trial studies how well giving azacitidine and entinostat work in treating patients with advanced breast cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Enti...
What is the current status of trial NCT01349959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2011-08-15. Estimated completion is 2023-11-07.
What conditions does trial NCT01349959 study?
This clinical trial studies the following conditions: Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IIIC Breast Cancer AJCC v7, Male Breast Carcinoma.
What interventions are being tested in trial NCT01349959?
The interventions under investigation include: Azacitidine (DRUG), Laboratory Biomarker Analysis (OTHER), Entinostat (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01349959?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01349959 being conducted?
This trial has 7 study locations across California, Maryland, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Breast Carcinoma
All registered trials for this condition
Triple-Negative Breast Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.